NATIVE: first clinical trial demonstrating…
The authors examined the effects of lanifibranor, a pan-agonist of the peroxisome proliferator–activated receptors with favourable effects on glucose and lipid metabolism….
Read More
Lanifibranor in NASH: NATiV3, an ongoing phase 3 trial
The New England Journal of Medicine has published the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH.
Read More
New targets for NAFLD
In this review, the authors provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets
Read More
Emerging drugs targeting specific points in NASH pathogenesis
Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials.
Read More
Pharmacotherapy in NAFLD/NASH
This review by S. L. Attia et al. summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD.
Read More
PPARs as candidates for the treatment of NAFLD
In this review, A. Fougerat et al. describe the determinants and mechanisms underlying the pathogenesis of NAFLD.
Read More
Fibrosis in NASH: targeted therapies
This review by T. M. Huisman et al. highlights key experimental and investigational therapies for NASH fibrosis, whose evaluation will be accelerated as new non-invasive markers of fibrosis are established.
Read More
Management of NAFLD: a review
As explained in the review by M. L. Petroni et al., several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Read More
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
Boyer-Diaz Z et al. tried to evaluate the therapeutic potential of pan-PPAR activation for the treatment of advanced cirrhosis. Read More
Read More
PPARs and immune responses
In their review, A. Christofides and colleagues discuss the actions of PPARs in the function of the innate and the adaptive immune system and their implications in immune-mediated inflammatory. Read More
Read More